An experimental compound derived from a long-abandoned class of synthetic opioids showed powerful short-term pain relief in animal tests while avoiding the classic dangers tied to standard opioids, and researchers see potential for safer pain medicines if human trials confirm the early results.
Researchers at the National Institute on Drug Abuse examined nitazenes, a family of synthetic opioids first synthesized decades ago and shelved because of extreme potency and addiction risk. These compounds have since reemerged on illegal markets and prompted concern among public health experts. The team set out to study whether modified versions could keep pain-killing effects while shedding the worst side effects.
“Nitazenes are a dangerous group of drugs that have no medical indication and are highly addictive,” cautioned Dr. Marc Siegel, senior medical analyst. The group’s toxic reputation comes from doses that can be hundreds or thousands of times stronger than morphine, which makes them a serious contributor to overdoses. That history is why scientists approached the chemistry with both caution and curiosity.
Michael Michaelides, PhD, the study’s senior author, explained the experimental aim in straightforward terms. “We wanted to decrease the potency and create a potential therapeutic,” he said in a press release. “What we discovered exceeded our expectations.” The result was a metabolite called DFNZ that behaved quite differently from the parent nitazenes.
FIRST-OF-ITS-KIND FENTANYL VACCINE TARGETS OVERDOSES BEFORE THEY START
In rodent models, a single dose of DFNZ delivered measurable pain relief within minutes and sustained it for a couple of hours, suggesting a fast onset and useful duration for acute pain care. Importantly, the usual red flags seen with standard opioids—marked respiratory slowing and clear signs of tolerance—did not appear in these preclinical trials. That profile would be a major shift if replicated in people.
“At preclinical therapeutic doses, DFNZ produced a moderate and sustained increase in brain oxygen rather than depressing respiration,” the authors wrote. That contrasts sharply with how many opioids depress breathing, a primary mechanism behind fatal overdoses. “Repeated doses of the drug did not result in tolerance, drug dependency or meaningful withdrawal effects.”
Those findings prompted cautious optimism from other experts. “Opioid pain medications are essential for medical purposes, but can lead to addiction and overdose,” said Nora D. Volkow, MD, director of NIH’s National Institute on Drug Abuse. “Developing a highly effective pain medication without these drawbacks would have enormous public health benefits.” The study’s authors say DFNZ binds tightly to opioid receptors but seems to trigger downstream signals in a safer way.
DFNZ’s pharmaceutic behavior appears to combine strong analgesia with softer reward and respiratory effects, which may be similar to how partial agonists act in certain contexts. “DFNZ has an unprecedented pharmacology for an opioid,” Michaelides said. “It is a potent and high-efficacy analgesic, but in certain contexts it resembles partial agonists, drugs that activate the receptor with low efficacy, which is what scientists think is needed for safety.”
“Its capacity to be administered at therapeutic doses without producing respiratory depression is very important.” That remains the headline finding: pain relief without the breathing suppression that makes opioids so dangerous in overdoses. Still, the work so far lives entirely in animal models, and translating safety from rats to humans is rarely simple.
Practical caveats came from clinicians who follow pain and spine care. “This new drug claims to release a lower-dose opioid alternative that might be able to offer pain relief without the addictive properties,” said Dr. Hooman Melamed, a board-certified orthopedic spine surgeon. “It’s also important to note that this has not been tested on humans, and we don’t know how this will impact people in the long run.”
Melamed warned about narrow therapeutic windows common to this chemistry. “In other words, a small increase in the dosage could become addictive for people, and without solid human data, we just can’t know the dependency risk,” he said. He also noted ancillary risks tied to opioid use: “Many opioids are known to slow down intestinal mobility, leading to issues like constipation and impaired digestion.”
“This is part of the reason I avoid prescribing opioids, because they can potentially weaken immune function and even contribute to broader systemic issues, such as inflammation or ‘leaky gut,'” he went on. “These issues can slow down one’s recovery.” The authors acknowledge the limits of their study and call for careful, measured progression to human safety testing.
